IDO1 and melanoma: Then, we applied 11C-l-1MTrp to longitudinally monitor whole-body IDO1 variations in immunocompetent melanoma-bearing mice treated with l-1MTrp plus either chemotherapeutic drugs or antibodies targeting PD-1 and CTLA4.